Artwork

Conteúdo fornecido por Gastro Broadcast. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Gastro Broadcast ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !

Episode #49: Treating C. diff by Reducing the Associated Inflammation (research shows that it works in mice)

17:14
 
Compartilhar
 

Manage episode 379414484 series 3382401
Conteúdo fornecido por Gastro Broadcast. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Gastro Broadcast ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Dr. Lisa Mathews interviews Dr. Min Dong and Dr. Meenakshi Rao of the Boston Children’s Hospital regarding new research published in Nature that shows two FDA-approved drugs can alter our body’s own immune response to treat Clostridioides difficile (C. diff) more effectively. C. diff is the leading cause of gastrointestinal infections in the United States, and existing medications don’t always work because of antibiotic resistance, the presence of more lethal strains, and a drugs’ potential to harm good gut bacteria that prevent infection. The study conducted by Dr. Dong and Dr. Rao found that two already approved medications reduced inflammation associated with C. diff infection in mice, allowing for their immune systems to mount a more productive response to the infection. Listen to Dr. Mathew, Dr. Dong, and Dr. Rao as they explore what the next steps are for this research and what it might mean for the future of treating patients with C. diff. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 49
  continue reading

61 episódios

Artwork
iconCompartilhar
 
Manage episode 379414484 series 3382401
Conteúdo fornecido por Gastro Broadcast. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Gastro Broadcast ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Dr. Lisa Mathews interviews Dr. Min Dong and Dr. Meenakshi Rao of the Boston Children’s Hospital regarding new research published in Nature that shows two FDA-approved drugs can alter our body’s own immune response to treat Clostridioides difficile (C. diff) more effectively. C. diff is the leading cause of gastrointestinal infections in the United States, and existing medications don’t always work because of antibiotic resistance, the presence of more lethal strains, and a drugs’ potential to harm good gut bacteria that prevent infection. The study conducted by Dr. Dong and Dr. Rao found that two already approved medications reduced inflammation associated with C. diff infection in mice, allowing for their immune systems to mount a more productive response to the infection. Listen to Dr. Mathew, Dr. Dong, and Dr. Rao as they explore what the next steps are for this research and what it might mean for the future of treating patients with C. diff. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 49
  continue reading

61 episódios

Todos os episódios

×
 
Loading …

Bem vindo ao Player FM!

O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.

 

Guia rápido de referências